US FDA approves Korean interferon alpha

Hanall Biopharma has recently announced it has received approval from the U.S. Food and Drug Administration to conduct phase II clinical trial of HanferonTM Inj. (interferon alpha) for the treatment of hepatitis C.

Last September, the company filed the IND application entitled “Phase 1b/2a, Open-Label, Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic and Prelim...